Search Results

From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general

. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics

the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.

Terry Hébert is a Professor within the Department of Pharmacology & Therapeutics at McGill University

Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes

of GPCRs in disease states to help test the feasibility of using protein-targeted degradation as a therapeutic

biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic

We hope our research will aid in the development of new therapeutic interventions for the alleviation

embody the multifaceted nature of GPCRs, showcasing their complexity, versatility, and potential for therapeutic

He is also an Associate Leader of the Experimental Therapeutics and Metabolism Program and the Director

As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery

She has advanced the use of computational methods to meet the challenges of designing therapeutics with

Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

clinical stage company developing next generation immunotherapies, and member of the SAB of Domain Therapeutics

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic

record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics

vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics

His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics

The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic

Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics

of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics

Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic

protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics

nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).

Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations